

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/065547 A2

(51) International Patent Classification⁷: C12N

(21) International Application Number:
PCT/US2004/001196

(22) International Filing Date: 16 January 2004 (16.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/440,699 17 January 2003 (17.01.2003) US

(71) Applicant (for all designated States except US): **THE RE-
SEARCH FOUNDATION OF THE STATE UNIVER-
SITY OF NEW YORK** [US/US]; P.O. Box 9, Albany, NY
12201 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MICHL, Josef**
[DE/US]; 251-26 Gaskell Road, Little Neck, NY 11362

(US). **BRADU, Stefan, M.** [US/US]; 85-19 65th Road,
Rego Park, NY 11374 (US). **HANNAN, Raquib** [US/US];
1842 Albermarle Avenue, East Meadow, NY 11554
(US). **PINCUS, Matthew, R.** [US/US]; Eastern Parkway,
Brooklyn, NY (US).


(74) Agents: **POKALSKY, Ann, R.** et al.; Dilworth & Barrese,
LLP, 333 Earle Ovington Boulevard, Uniondale, NY 11553
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: PANCREATIC CANCER ASSOCIATED ANTIGEN, ANTIBODY THERETO, AND DIAGNOSTIC AND TREAT-
MENT METHODS



(57) Abstract: The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Agl, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Agl exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.